Compare PRTA & CVLG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRTA | CVLG |
|---|---|---|
| Founded | 2012 | 1986 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trucking Freight/Courier Services |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 539.9M | 634.1M |
| IPO Year | 2013 | 1996 |
| Metric | PRTA | CVLG |
|---|---|---|
| Price | $11.10 | $34.77 |
| Analyst Decision | Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $19.00 | N/A |
| AVG Volume (30 Days) | ★ 388.4K | 152.1K |
| Earning Date | 05-07-2026 | 04-23-2026 |
| Dividend Yield | N/A | ★ 0.80% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.27 |
| Revenue | $814,000.00 | ★ $705,007,000.00 |
| Revenue This Year | $1,111.38 | $7.17 |
| Revenue Next Year | N/A | $7.53 |
| P/E Ratio | ★ N/A | $128.91 |
| Revenue Growth | N/A | ★ 5.12 |
| 52 Week Low | $4.32 | $18.00 |
| 52 Week High | $11.69 | $35.91 |
| Indicator | PRTA | CVLG |
|---|---|---|
| Relative Strength Index (RSI) | 60.89 | 79.37 |
| Support Level | $9.69 | $22.75 |
| Resistance Level | $11.63 | N/A |
| Average True Range (ATR) | 0.39 | 1.26 |
| MACD | 0.01 | 0.52 |
| Stochastic Oscillator | 66.19 | 86.04 |
Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.
Covenant Logistics Group Inc together with its wholly-owned subsidiaries, offers truckload transportation and freight brokerage services to customers throughout the continental United States. The company's reportable segments include Expedited, Dedicated Services, Managed Freight, and Warehousing. The expedited segment provides truckload services to customers with high service freight and delivery standards. Dedicated segment provides customers with committed truckload capacity over contracted periods with the goal of three to five years in length. The Managed Freight segment includes brokerage services and TMS. The warehousing segment provides day-to-day warehouse management services to customers who have chosen to outsource this function.